Dermatology Consulting Services, PLLC, High Point, North Carolina, USA.
J Cosmet Dermatol. 2024 Nov;23(11):3662-3666. doi: 10.1111/jocd.16602. Epub 2024 Sep 27.
Facial erythema from acne, vascular rosacea, or photoaging is a common difficult-to-treat dermatologic challenge.
The objective of this study was to examine the role of lapachol in alleviating facial erythema associated with a variety of common dermatologic conditions.
Twenty-five healthy female and male subjects 35-65 years of age of Fitzpatrick skin types I-II with mild-to-moderate stable facial erythema from acne, rosacea or photoaging were enrolled in a single-site monadic study. Subjects received the study cream for twice daily application and were assessed at baseline, Week 4, and Week 8. The dermatologist investigator and subjects assessed efficacy and tolerability and facial photographic images were taken of all subjects at each visit. Noninvasive erythema assessments of the face were conducted using a colorimeter at baseline, Week 4, and Week 8 to document improvement in facial erythema.
Twenty-five out of 25 subjects successfully completed the study without tolerability issues including 12 subjects with rosacea, 6 subjects with photoaging and 7 subjects with acne. After 8 weeks of use, the investigator rated a 44% decrease in facial erythema while the subjects rated a 40% decrease. Facial erythema was also noninvasively assessed with a colorimeter and dermaspectrophotometer (DSP). There was a 26% decrease in skin redness at Week 4 and a 31% decrease in skin redness at Week 8 on the colorimeter Lab* scale. This finding was collaborated by the DSP which registered a 29% decrease on the erythema scale at Week 8.
Lapachol in a moisturizer formulation was found to be effective in reducing facial erythema from acne, rosacea, and photoaging.
痤疮、血管性玫瑰痤疮或光老化引起的面部红斑是一种常见的、难以治疗的皮肤科挑战。
本研究旨在探讨拉帕醇在缓解痤疮、玫瑰痤疮或光老化引起的各种常见皮肤科疾病相关面部红斑中的作用。
25 名年龄在 35-65 岁、皮肤类型为 Fitzpatrick I-II 的健康男女受试者，面部有轻度至中度稳定的红斑，来自痤疮、玫瑰痤疮或光老化，参与了一项单中心、单盲研究。受试者每天接受两次研究乳膏治疗，并在基线、第 4 周和第 8 周进行评估。皮肤科医生研究者和受试者评估疗效和耐受性，并在每次就诊时对所有受试者进行面部拍照。在基线、第 4 周和第 8 周使用色差仪进行非侵入性面部红斑评估，以记录面部红斑的改善情况。
25 名受试者均成功完成研究，无耐受性问题，其中 12 名受试者患有玫瑰痤疮，6 名受试者患有光老化，7 名受试者患有痤疮。使用 8 周后，研究者评估面部红斑减少 44%，而受试者评估红斑减少 40%。面部红斑也通过色差仪和皮肤分光光度计（DSP）进行了非侵入性评估。在第 4 周时，皮肤红色程度在 Lab*颜色标尺上下降了 26%，在第 8 周时下降了 31%。这一发现与 DSP 相吻合，后者在第 8 周时在红斑量表上登记了 29%的下降。
保湿剂配方中的拉帕醇被发现可有效减少痤疮、玫瑰痤疮和光老化引起的面部红斑。
